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Sigma-1 (σ1) receptor antagonists are promising tools for neuropathic pain treatment, but 
it is unknown whether σ1 receptor inhibition ameliorates the neuropathic signs induced 
by nerve transection, in which the pathophysiological mechanisms and response to drug 
treatment differ from other neuropathic pain models. In addition, σ1 antagonism ameliorates 
inflammatory pain through modulation of the endogenous opioid system, but it is unknown 
whether this occurs during neuropathic pain. We investigated the effect of σ1 inhibition on 
the painful hypersensitivity associated with the spared nerve injury (SNI) model in mice. Wild-
type (WT) mice developed prominent cold (acetone test), mechanical (von Frey test), and 
heat hypersensitivity (Hargreaves test) after SNI. σ1 receptor knockout (σ1-KO) mice did not 
develop cold allodynia and showed significantly less mechanical allodynia, although they 
developed heat hyperalgesia after SNI. The systemic acute administration of the selective σ1 
receptor antagonist S1RA attenuated all three types of SNI-induced hypersensitivity in WT 
mice. These ameliorative effects of S1RA were reversed by the administration of the σ1 agonist 
PRE-084, and were absent in σ1-KO mice, indicating the selectivity of S1RA-induced effects. 
The opioid antagonist naloxone and its peripherally restricted analog naloxone methiodide 
prevented S1RA-induced effects in mechanical and heat hypersensitivity, but not in cold 
allodynia, indicating that opioid-dependent and -independent mechanisms are involved in 
the effects of this σ1 antagonist. The repeated administration of S1RA twice a day during 
10 days reduced SNI-induced cold, mechanical, and heat hypersensitivity without inducing 
analgesic tolerance during treatment. These effects were observed up to 12 h after the last 
administration, when S1RA was undetectable in plasma or brain, indicating long-lasting 
pharmacodynamic effects. These data suggest that σ1 antagonism may have therapeutic 
value for the treatment of neuropathic pain induced by the transection of peripheral nerves.
Keywords: neuropathic pain, spared nerve injury, sigma-1 receptors, S1RA, endogenous opioid system, 
mechanical allodynia, cold allodynia, heat hyperalgesia
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INTRODUCTION
Neuropathic pain is a debilitating chronic pain condition resulting 
from a lesion or disease of the somatosensory system (Colloca 
et al., 2017). The prevalence of neuropathic pain in the general 
population has been estimated in the range of 6.9–10% (van Hecke 
et al., 2014), and it is expected to rise in the future (Colloca et al., 
2017). Despite the enormous efforts devoted to both clinical and 
preclinical research, neuropathic pain treatment remains an unmet 
clinical need (Finnerup et al., 2015).
The sigma-1 (σ1) receptor is a unique ligand-operated chaperone 
expressed at high levels in several key pain control areas in both 
the peripheral and central nervous system, where it interacts 
with different receptors and ion channels to modulate them (Su 
et al., 2016; Sánchez-Fernández et al., 2017). The pharmacology 
of σ1 receptors has been deeply studied, and there are currently 
selective σ1 agonists (such as PRE-084) and antagonists (such as 
S1RA), to study σ1 receptor function (Sánchez-Fernández et al., 
2017). Substantial evidence points to a prominent role for these 
receptors in neuropathic pain of diverse etiology (Merlos et al., 
2017; Sánchez-Fernández et al., 2017), and shows that pain-like 
behaviors are attenuated in σ1-knockout (KO) mice (de la Puente 
et al., 2009; Nieto et al., 2012) and in wild-type (WT) animals 
treated with σ1 receptor antagonists (Roh et al., 2008; Nieto et al., 
2012; Romero et al., 2012; Gris et al., 2016; Kang et al., 2016). 
The mechanisms involved in the antineuropathic effects of σ1 
inhibition are only partially known and have been well studied in 
the central nervous system, specifically in the dorsal spinal cord, 
where these receptors control central sensitization (reviewed in 
Sánchez-Fernández et al., 2017).
There are differences between the pathophysiological mechanisms 
and responses to drug treatment for neuropathic pain induced 
by different types of injury to the peripheral nerves (Aley and 
Levine, 2002; Baron et al., 2010; Hershman et al., 2014; Finnerup 
et al., 2015). In particular, different neuroplastic changes (Casals-
Díaz et al., 2009) and gene expression profiles (Griffin et al., 2007; 
Costigan et al., 2010) have been reported after denervation or 
constriction/ligation of the sciatic nerve. Surgical interventions 
inevitably results in nerve transection, and as a consequence, 
significant number of patients experience neuropathic pain 
(Borsook et al., 2013). However, all studies to date on the role of σ1 
receptors in neuropathic pain after mechanical injury to peripheral 
nerves has focused on models of sciatic nerve constriction/
ligation (Roh et al., 2008; de la Puente et al., 2009; Espinosa-Juárez 
et al., 2017a); thus the role of σ1 receptors in neuropathic pain 
induced by nerve transection has never been explored. Transection 
of the tibial and common peroneal branches of the sciatic nerve 
results in persistent neuropathic pain in rodents, manifested by 
marked hypersensitivity in the territory of the intact sural branch. 
Hence, this neuropathic pain model is termed the spared nerve 
injury (SNI) model (Decosterd and Woolf, 2000).
In view of these antecedents, the first goal of the present study 
was to test whether the inhibition of σ1 receptors alleviated the 
painful hypersensitivity associated with SNI-induced neuropathic 
pain. This was investigated by comparing SNI-induced neuropathic 
hypersensitivity in WT and σ1-KO mice, and by testing the effects, in 
animals with neuropathy, of the acute and repeated administration 
of the selective σ1 antagonist S1RA, which is currently under clinical 
development for the treatment of neuropathic pain (Abadias et al., 
2013; Bruna et al., 2018).
Opioid receptors have been described as part of the interactome 
of σ1 receptors. This is relevant since σ1 receptors physically interact 
with opioid receptors restraining their functioning (reviewed in 
Sánchez-Fernández et al., 2017), so that σ1 receptor inhibition 
enhances analgesia induced by opioid drugs in nociceptive pain 
at both central (Mei and Pasternak, 2002) and peripheral sites 
(Sánchez-Fernández et al., 2013; Sánchez-Fernández et al., 2014; 
Prezzavento et al., 2017), and can increase the antihyperalgesic 
effects of endogenous opioid peptides (EOPs) produced naturally 
by immune cells that accumulate at the inflamed site to relieve 
inflammatory pain (Tejada et al., 2017). During neuropathic pain 
there is a prominent recruitment of immune cells harboring EOPs 
at both peripheral and central sites (reviewed in Ref. Tejada et al., 
2018). However, whether σ1 receptors modulate endogenous 
opioid analgesia in neuropathic pain remains completely unknown. 
Therefore, the second goal of this study was to evaluate the possible 
contribution of the endogenous opioid system to the antineuropathic 
effects induced by S1RA in the mouse model of SNI.
METHODS
Animals
Most experiments were performed in 8- to 11-week-old female 
WT CD-1 mice (Charles River, Barcelona, Spain) and σ1-KO CD-1 
mice (Laboratorios Esteve, Barcelona, Spain). Some experiments 
were performed on male mice from the same strain and genotypes. 
Taking into account that male mice are much more aggressive to 
other mice than female animals (Edwards, 1968), and that stress 
such us that induced by fights with the alpha male can induce 
opioid analgesia (Miczek et al., 1982), we considered that this 
behavior of male mice might be a confounder in our experiments in 
the context on the modulation of endogenous opioid analgesia by 
σ1 receptors. Therefore, we performed most experiments in female 
mice. However, we also tested male mice in some key experiments 
(see the Results section) to explore a possible sexual dimorphism in 
σ1-mediated modulation of SNI-induced hypersensitivity. Female 
animals were tested at random times throughout the estrous cycle. 
Mice were housed in colony cages with free access to food and 
water prior to the experiments, and were kept in temperature- and 
light-controlled rooms (22 ± 2°C, and light–dark cycle of 12 h). 
The experiments were done during the light phase (from 9:00 a.m. 
to 3:00 p.m.). Animal care was in accordance with international 
standards (European Communities Council Directive 2010/63), 
and the protocol of the study was approved by the Research Ethics 
Committee of the University of Granada, Spain.
Spared Nerve Injury
Mice were anesthetized with isoflurane (2%), and SNI surgery was 
performed as previously described (Bourquin et al., 2006). Briefly, 
an incision was made in the left thigh skin and was followed by 
Abbreviations: EOP, endogenous opioid peptide; i.p., intraperitoneal; KO, knockout; 
σ1, sigma-1; SNI, spared nerve injury; WT, wild-type.
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an incision made directly through the biceps femoris muscle, 
exposing the sciatic nerve and its three terminal branches (the 
sural, common peroneal, and tibial nerves). The tibial and common 
peroneal branches of the sciatic nerve were ligated with a silk 
suture and transected distally, while the sural nerve was left intact. 
In sham-operated control mice, the sciatic nerve terminal branches 
were exposed but neither ligated nor transected. The day of SNI 
surgery is referred to as day 0. In some mice, SNI surgery induced 
hypoesthesia/anesthesia in the territory of the paw innervated by 
the sural nerve, instead of inducing sensory hypersensitivity. This 
was considered to be a consequence of a failed surgery and the 
mice were discontinued from further evaluations. These mice 
accounted for less than 1% of the mice tested.
Drugs and Drug Administration
Acute Treatment Protocol
We used two selective σ1 receptor ligands: the σ1 antagonist S1RA 
(E-52862.HCl; 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol- 
3-yl]oxy]ethyl] morpholine) (8–128 mg/kg; DC Chemicals, 
Shanghai, China), and the σ1 agonist PRE-084 (2-[4-morpholinethyl]1-
phenylcyclohexanecarboxylate hydrochloride) (Tocris Cookson Ltd., 
Bristol, United Kingdom) (Cobos et al., 2008). In addition, we used 
the following opioid receptor ligands: the opioid agonist morphine 
hydrochloride (0.5–2 mg/kg; General Directorate of Pharmacy and 
Drugs, Spanish Ministry of Health), the opioid antagonist naloxone 
hydrochloride and its peripherally restricted analog naloxone 
methiodide (Sigma-Aldrich, Madrid, Spain). The doses of S1RA s.c. 
(subcutaneously) and morphine used to reverse mechanical, heat, 
and cold hypersensitivities were determined in the experiments 
shown in the “Results” section. The dose of PRE-084 used in the 
present study (32 mg/kg, s.c.) was selected based on our previous 
studies (Entrena et al., 2009; Montilla-García et al., 2018). The 
doses of naloxone (1 mg/kg, s.c.) and naloxone methiodide (2 mg/
kg, s.c.) are those used in our previous studies (Sánchez-Fernández 
et al., 2014; Tejada et al., 2017). All drugs were dissolved to their 
final concentrations in sterile physiological saline just before 
administration, and were administered subcutaneously (s.c.) in the 
interscapular area in an injection volume of 5 mL/kg. The control 
animals received the same volume of the drug solvent (saline) 
s.c. All drugs were administered 7 days after surgery, when pain 
hypersensitivity was fully developed, and their effects were tested 
as explained in the Behavioral Assays section. When the effects 
of the association of two different drugs were evaluated, each 
injection was performed in a different area of the interscapular 
zone. In all cases, behavioral evaluations after drug administration 
were performed by an observer blinded to the treatment.
Repeated (10 days) Treatment Protocol
Treatment was given twice a day (every 12 h) via the intraperitoneal 
(i.p.) route with S1RA 25 mg/kg or vehicle, since it has been previously 
described that S1RA was efficacious using this administration 
protocol in a model of neuropathic pain induced by nerve ligation 
(Romero et al., 2012). Treatment started in the day of surgery (first 
injection 30 min before the injury) and was maintained for up 
to day 9 (i.e., 10 days of treatment). The effects of treatments were 
evaluated on days 7 (30 min after the administration of S1RA or 
saline), 10 (12 h after the last administration of S1RA or saline), 11, 
and 14 after nerve injury (36 and 108 h after the last administration of 
S1RA or saline, respectively) in each animal. Behavioral evaluations 
after repeated drug administration were performed by an observer 
blinded to the treatment.
Behavioral Assays
Time Course Studies
To elucidate the time course of SNI-induced pain hypersensitivity 
in WT and σ1-KO mice, the behavioral responses were tested 
before surgery (baseline value). Then SNI surgery was performed 
and behavioral tests were carried out 3, 7, 14, and 21 days after SNI 
in each animal.
To investigate the acute effects of drugs on pain-related 
behaviors associated with SNI, presurgery baseline responses 
were evaluated, and then SNI surgery was performed. Seven days 
after the surgical procedure, when SNI-induced mechanical, heat, 
and cold hypersensitivities were fully developed, pretreatment 
measurements were made (time 0) and then the drugs or saline 
were injected s.c., and the response of the animal to the nociceptive 
test was measured again 30, 90, and 180 min after the injection.
In all cases, each mouse was evaluated in only one nociceptive 
test and received drug treatment or saline only once. All 
behavioral evaluations were recorded by an observer blinded to 
the genotype and treatment.
Procedure to Measure Mechanical Allodynia
Mechanical allodynia was assessed with von Frey filaments 
according to the up–down method (Chaplan et al., 1994), with slight 
modifications. On each day of evaluation the mice were habituated 
for 60 min in individual transparent plastic boxes (7 × 7 × 13 cm) 
placed on a wire mesh platforms. After the acclimation period, 
filaments were applied to the plantar ipsilateral hind paw in the 
sural nerve territory, pressed upward to cause a slight bend in the 
fiber, and left in place for 2–3 s. Calibrated von Frey monofilaments 
(Stoelting, Wood Dale, IL, USA) with bending forces that ranged 
from 0.02 to 1.4 g were applied using the up–down paradigm, 
starting with the 0.6 g filament and allowing 10 s between successive 
applications. The response to the filament was considered positive 
if immediate licking/biting, flinching, or rapid withdrawal of the 
stimulated paw was observed. In each consecutive test, if there was 
no response to the filament, a stronger stimulus was then selected; if 
there was a positive response, a weaker one was then used.
Procedure to Measure Cold Allodynia
Cold allodynia was tested by gently touching the plantar skin 
of the hind paw with an acetone drop, as previously described 
(Nieto et al., 2008). On each day of evaluation the mice were 
housed and habituated for 30 min in individual transparent 
plastic enclosures (7 × 7 × 13 cm) with a floor made of wire 
mesh. Acetone was applied three times to the ipsilateral hind 
paw at intervals of 30 s, and the duration of biting or licking of 
the hind paw was recorded with a stopwatch and reported as the 
cumulative time of biting/licking in all three measurements. A 
cutoff time of 10 s was used in each of the three trials, because 
animals rarely licked their hind paw for more than 10 s. During 
Sigma-1 Receptors and Neuropathic PainBravo-Caparrós et al.
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the presurgery baseline evaluation we discarded ≈ 5% of the mice 
tested due to an exaggerated atypical response to the acetone 
(>5 s of cumulative responses to acetone in the three measures).
Procedure to Measure Heat Hyperalgesia
To measure heat hyperalgesia we used the Hargreaves method 
(Tejada et al., 2014), with slight modifications as previously 
described (Hargreaves et al., 1988). Mice were habituated for 2 h 
in individual plastic chambers (9 × 9 × 22 cm) placed on a glass 
floor maintained at 30°C. After habituation, a beam of radiant 
heat was focused to the plantar surface of the ipsilateral hind paw 
with a plantar test apparatus (IITC, Los Angeles, CA, USA), until 
the mouse made a withdrawal response. Each mouse was tested 
three times, and the latencies were averaged for each animal. At 
least 60 s were allowed between consecutive measurements. A 
cutoff latency time of 20 s was used in each measurement to avoid 
lesions to the skin and unnecessary suffering.
Determination of the Concentration 
of S1RA in Plasma and Brain Tissue
Animals were treated as described in the Repeated (10 Days) 
Treatment Protocol section, and the concentration of S1RA in 
plasma and brain tissue was measured 30 min and 12 h after the last 
i.p. administration. Briefly, a terminal blood sample was drawn from 
each mouse by cardiac puncture at the appropriate time after vehicle 
or drug administration. Blood samples were collected in heparinized 
tubes and centrifuged at 2,000 × g for 10 min to obtain plasma. 
Immediately after blood extraction, whole brains were removed. 
Plasma samples and brains were stored at −80°C until analysis. Each 
brain was weighted and homogenized in 4 mL Dulbecco’s phosphate 
buffered saline immediately before drug concentrations were 
determined. Protein was precipitated with acetonitrile, and samples 
were analyzed by high-performance liquid chromatography–
triple quadrupole mass spectrometry (HPLC-MS/MS) according 
to a previously described procedure (Romero et al., 2012). The 
concentration of the compound in plasma or brain was determined 
by least-squares linear regression with a calibration curve.
Data Analysis
For behavioral studies, statistical analysis was carried out with 
two-way repeated-measures analysis of variance (ANOVA). 
For the study of the S1RA levels determined by HPLC-MS/MS 
assay, statistical analysis was performed with two-way ANOVA. 
The Bonferroni post hoc test was performed in all cases. The 
differences between values were considered significant when the 
p-value was below 0.05. All data were analyzed with SigmaPlot 
12.0 software (Systat Software Inc., San Jose, CA, USA).
RESULTS
Comparison of Spared Nerve Injury-
Induced Neuropathic Pain in σ1 Receptor 
Knockout and Wild-Type Mice
We studied the involvement of the σ1 receptor in neuropathic pain 
after SNI by comparing the response to mechanical, heat, and cold 
stimuli in WT and σ1-KO female mice. The baseline responses 
to the von Frey, Hargreaves, and acetone tests before surgery 
did not differ significantly between σ1-KO and WT animals in 
any group tested (Figure 1A–C). In the sham-operated groups 
there were no significant postsurgery changes in the responses to 
any of the three behavioral tests in either σ1-KO or WT animals 
(Figure 1A–C). However, after SNI surgery, WT mice developed 
mechanical allodynia, manifested as a significant reduction in 
the mechanical threshold, which was detectable as early as day 
3 after surgery, was greatest on day 7, and remained observable 
throughout the 21-day evaluation period. σ1-KO mice also 
developed mechanical allodynia; however, it was significantly less 
FIGURE 1 | Comparison of spared nerve injury (SNI)-induced neuropathic pain behaviors in female wild-type (WT) and σ1 receptor knockout (KO) mice. The von 
Frey threshold (A), latency to hind paw withdrawal in the Hargreaves test (B), and duration of hind paw licking or biting in the acetone test (C) were recorded 1 day 
before (baseline, BL) and on days 3, 7, 14, and 21 after surgery in the paw ipsilateral to the surgery. Each point and vertical line represent the mean ± SEM of the 
values obtained in 10–12 animals. Statistically significant differences between the values in the sham and SNI groups on the same day: *P < 0.05; **P < 0.01; and 
among WT and KO groups: ##P < 0.01 (two-way repeated-measures ANOVA followed by Bonferroni test).
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pronounced than in WT mice, and the differences between WT 
and σ1-KO mice were statistically significant from day 7 to day 21 
(Figure 1A). Both WT and σ1-KO mice developed a similar 
degree of heat hypersensitivity in the Hargreaves test after SNI, 
with paw withdrawal latencies to heat stimulation significantly 
lower than those in sham-operated mice of both genotypes and at 
all time points evaluated after SNI (Figure 1B). Wild-type mice 
with SNI also developed marked cold allodynia, manifested as a 
significantly longer increase in the duration of paw licking/biting 
induced by acetone from day 3 throughout the evaluation period 
in comparison to the control WT sham group (Figure 1C). In 
contrast, SNI surgery had no significant effect on the postsurgery 
responses in σ1-KO mice in the acetone test, given that the values 
in this group were virtually identical to those in the σ1-KO sham 
group throughout the evaluation period (Figure 1C). These 
results are summarized in Table 1.
We also compared mechanical, heat, and cold hypersensitivities 
induced by SNI in female and male animals from both genotypes. 
On day 7 after SNI, sensory hypersensitivity to the three types 
of stimuli was equivalent in WT female and male mice (Figure 2). 
σ1-KO mice of both sexes showed an equivalent reduction  of 
mechanical allodynia, while showing the same extent of  heat 
hyperalgesia than WT mice, but no cold hypersensitivity 
(Figure 2A–C, respectively).
In summary, SNI surgery induced mechanical, heat, and 
cold hypersensitivity in WT mice of both sexes. However, SNI 
surgery led to a clearly different pattern of neuropathic signs 
in σ1-KO mice irrespectively of the sex tested, as these female 
or male mutant mice developed heat hyperalgesia, but did not 
develop cold allodynia and showed significantly less mechanical 
allodynia.
Effects of the Acute Systemic 
Administration of the Selective σ1 Receptor 
Antagonist S1RA on Spared Nerve Injury-
Induced Mechanical, Cold, and Heat 
Hypersensitivity
To test the effects of acute pharmacological antagonism by the 
σ1 receptor on SNI-induced neuropathic pain, the selective σ1 
receptor antagonist S1RA was administered s.c. to female WT 
mice after neuropathy was fully developed (7 days after surgery). 
The threshold force needed to evoke pain-like responses before 
treatment with S1RA or saline was significantly lower than in 
the baseline measurement (Figure 3A, time 0), thus showing 
mechanical allodynia. Saline administration did not significantly 
modify SNI-induced mechanical allodynia during the 3-h test 
period (Figure 3A). In contrast, the acute administration of 
S1RA (32–128 mg/kg) attenuated mechanical allodynia in a 
dose-dependent manner (Figure 3A). In mice with SNI, paw 
withdrawal latencies to radiant heat were significantly shorter, 
in comparison to their baseline measurements, in all groups 
of animals before S1RA or saline administration (Figure 3B, 
time 0). Saline administration did not significantly modify SNI-
induced heat hyperalgesia, whereas the s.c. administration of 
S1RA (25–64 mg/kg) dose-dependently inhibited this response 
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before treatment with S1RA or saline (time 0) showed a longer 
duration of paw licking/biting in response to acetone (Figure 3C, 
time 0). In these mice, a single s.c. injection of saline did not 
modify the response to acetone at any of the time points tested 
(Figure 3C). However, a single s.c. injection of S1RA (8–64 mg/kg) 
dose-dependently reduced the duration of acetone-induced paw 
licking/biting from 30 to 90 min after treatment (Figure  3C). 
Among the three sensory modalities explored in female mice, cold 
allodynia was the most sensitive outcome to the effects of S1RA, 
as it was fully reversed by 16 mg/kg of this compound, whereas 
S1RA 64 mg/kg was needed to fully reverse heat hyperalgesia, 
and we had to increase the dose of S1RA up to 128  mg/kg to 
induce a prominent (although partial) effect on SNI-induced 
mechanical allodynia (compare Figure 3A–C). These results are 
summarized in Table 1.
In contrast to the effect of the σ1 receptor antagonist S1RA, 
the selective σ1 agonist PRE-084 (32 mg/kg, s.c.), when tested 
7 days after SNI, did not alter SNI-induced mechanical-, heat-, 
or cold-hypersensitivity in female WT mice (Figure 4A–C, 
respectively). However, when PRE-084 (32 mg/kg, s.c.) and S1RA 
were associated, the antiallodynic and antihyperalgesic effects 
of this σ1 antagonist were abolished (Figure 4A–C), suggesting 
FIGURE 2 | Comparison of SNI-induced neuropathic pain behaviors in female and male WT and σ1-KO mice. The von Frey threshold (A), latency to hind paw withdrawal in 
the Hargreaves test (B), and duration of hind paw licking or biting in the acetone test (C) were recorded 1 day before (baseline) and 7 days after surgery in the paw ipsilateral 
to the surgery. Each point and vertical line represent the mean ± SEM of the values obtained in 8–12 animals. Statistically significant differences between the values on the 
presurgery (baseline) day and 7 days after SNI in mice of the same sex: **P < 0.01; and between WT and KO groups of mice of the same sex: ##P < 0.01. There were no 
statistical differences between values from mice of different sexes under the same experimental conditions (two-way repeated-measures ANOVA followed by Bonferroni test).
FIGURE 3 | Time course of the effects of a single subcutaneous (s.c.) injection of S1RA (8–128 mg/kg) or saline on mechanical allodynia (A), heat hyperalgesia (B), 
and cold allodynia (C), in female WT mice with SNI, 7 days after surgery. The von Frey threshold (A), the latency to hind paw withdrawal in the Hargreaves test (B), 
and the duration of hind paw licking or biting in the acetone test (C) were recorded 1 day before (baseline, BL) and 7 days (Day 7) after surgery in the paw ipsilateral 
to the surgery. On day 7, the responses to test stimuli was recorded immediately before (time 0) and at several times (30, 90, and 180 min) after injection of the 
drug or saline. Each point and vertical line represent the mean ± SEM of the values obtained in 8–11 animals. Statistically significant differences between S1RA- and 
saline-treated groups at the same time after treatment: **P < 0.01 (two-way repeated-measures ANOVA followed by Bonferroni test).
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that the effects of S1RA were mediated by the pharmacological 
antagonism of σ1 receptors.
To further verify the role σ1 receptors on the effects induced 
by S1RA in SNI-induced hypersensitivity, we compared its effects 
in female WT and mice lacking σ1 receptors (σ1-KO mice). We 
tested the effects of this drug in σ1-KO mice only for SNI-induced 
mechanical allodynia, which was partially developed in these mice, 
and heat hypersensitivity, which fully developed in σ1-KO mice; 
whereas we did not test for the possible effects of S1RA on cold 
allodynia, since this type of hypersensitivity was absent in σ1-KO 
mice (as shown in Figure 1). WT mice given the σ1 antagonist 
S1RA showed less SNI-induced mechanical allodynia (Figure 
5A) and heat hyperalgesia (Figure 5B), but the administration of 
S1RA to σ1-KO mice did not induce significant antiallodynic or 
antihyperalgesic effects in these mutant mice (Figure 5A and B).
Therefore, both the reversion of the effects of S1RA by 
PRE-084 and the absence of activity of S1RA in mice lacking 
σ1 receptors suggest that off-target effects did not contribute 
to the antineuropathic effects of the σ1 antagonist S1RA in this 
neuropathic pain model.
Contribution of the Endogenous Opioid 
System to Antineuropathic Effects of the 
Systemic Administration of S1RA on Spared 
Nerve Injury-Induced Neuropathic Pain
In female WT mice, the association of the opioid antagonist 
naloxone (1 mg/kg, s.c.) with S1RA administered 7 days after SNI 
surgery completely reversed the ameliorative effects produced by 
the σ1 antagonist on hypersensitivity to mechanical (Figure 6A) 
and heat stimuli (Figure 6B). We also tested the effects of the 
peripherally restricted opioid antagonist naloxone methiodide on 
the antineuropathic effects of S1RA, and observed that peripheral 
opioid antagonism was also able to fully reverse the effects of 
S1RA on mechanical and heat hypersensitivity (Figure 6A and B). 
These data suggest that the effects induced by the σ1 antagonist 
on SNI-induced mechanical and heat hypersensitivity require 
the participation of the opioid system at the peripheral level. In 
contrast, naloxone treatment did not alter the effects of S1RA on 
cold allodynia (Figure 6C), suggesting that opioid-independent 
effects induced by S1RA were involved in the decrease in this type 
of hypersensitivity. These results are summarized in Table 1.
We tested these same doses of S1RA in male mice and found 
equivalent results than those found in female mice: the acute 
administration of the σ1 receptor antagonist S1RA to male 
mice partially reversed SNI-induced mechanical allodynia but 
completely reversed heat and cold hypersensitivity (Figure 6D–F, 
respectively). Similar to the results shown with female mice, 
the ameliorative effects of S1RA on mechanical and heat SNI-
induced hypersensitivity in male mice were reversed by naloxone 
methiodide, whereas naloxone did not reverse the effects of S1RA 
on cold allodynia (Figure 6D–F, respectively).
In order to explore whether the endogenous opioid system 
influences pain hypersensitivity induced by SNI in female mice, 
we administered naloxone (1 mg/kg) and naloxone methiodide 
(2 mg/kg) in the absence of S1RA to WT mice 7 days after SNI. No 
significant effects were observed with any of the opioid antagonists 
in any of the three sensory modalities explored (Figure 7A–C).
Effects of the Systemic Administration of 
Morphine on Spared Nerve Injury-Induced 
Cold and Mechanical Allodynia and Heat 
Hyperalgesia
To test the effects of an opioid drug on SNI-induced sensory 
hypersensitivity, we evaluated the effects of morphine in this 
FIGURE 4 | The σ1 receptor agonist PRE-084 reversed the effects of the σ1 receptor antagonist S1RA in female WT mice with SNI 7 days after surgery. Mechanical 
allodynia (A), heat hyperalgesia (B), and cold allodynia (C) were evaluated 1 day before (baseline, BL) and 7 days (day 7) after surgery, in the paw ipsilateral to the 
surgery. On day 7, the responses to test stimuli were recorded immediately before (time 0) and at several times (30, 90, and 180 min) after injection of the drugs 
or saline. Each point and vertical line represent the mean ± SEM of the values obtained in 8–14 animals. Statistically significant differences in comparison to the 
saline+S1RA group: *P < 0.05; **P < 0.01 (two-way repeated-measures ANOVA followed by Bonferroni test).
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neuropathic pain model in female mice. As expected, acute 
administration of the morphine solvent (saline) had no effect 
on hypersensitivity following SNI surgery (Figure 8A–C). 
However, the administration of morphine (1 and 2 mg/kg, s.c.) 
led to significantly less mechanical allodynia associated with 
SNI, with a more prolonged effect at the highest dose tested 
(Figure 8A). In addition, acute treatment with morphine (0.5 
and 1 mg/kg) inhibited, in a dose-dependent manner, both 
heat hyperalgesia (Figure 8B) and cold allodynia (Figure 8C) 
induced by SNI. Whereas a single s.c. injection of morphine 
(1 mg/kg) completely reversed heat and cold hypersensitivity 
induced by SNI, the effect of morphine on SNI-induced mechanical 
allodynia was weaker, leading to only a partial reduction (see 
Figure 8A–C).
To elucidate the possible contribution of peripheral opioid 
receptors to the antinociceptive effects induced by morphine in SNI 
mice, we associated morphine administration with the injection of 
the opioid antagonists naloxone or naloxone methiodide. As 
expected, naloxone (1 mg/kg s.c.) completely reversed the 
antinociceptive effect of morphine in all three sensory modalities 
explored, with values indistinguishable from those in mice 
treated with the drug solvent (Figure 9A–C). However, naloxone 
methiodide (2 mg/kg) completely reversed the effect of morphine 
(1 mg/kg) on mechanical allodynia (Figure 9A), and markedly 
reduced its effects on heat hyperalgesia (Figure 9B), whereas it did 
not reverse the effect of morphine on SNI-induced cold allodynia 
(Figure 9C). These data suggest that peripheral opioid receptors 
contributed to the ameliorative effects induced by morphine only 
in hypersensitivity to mechanical and heat stimuli induced by SNI, 
but not in cold allodynia.
Effect of Repeated Treatment With S1RA 
on Neuropathic Pain-Related Behaviors
To study the effect of prolonged pharmacological antagonism of 
the σ1 receptors on the development of SNI-induced neuropathy, 
we administered to WT female mice two daily injections of 
S1RA (25 mg/kg, i.p.) or saline, starting 30 min before surgery 
and continuing up to day 9. Mechanical allodynia (Figure 10A), 
heat hyperalgesia (Figure 10B), and cold allodynia (Figure 10C) 
induced by SNI were suppressed by the repeated administration 
of S1RA when measured on day 7 after surgery, 30 min after its 
administration.
The antineuropathic effects induced by repeated treatment with 
S1RA were still significant in all three sensory modalities explored 
(compared to treatment with the vehicle only) on day 10, 12 h 
after the last administration of S1RA (Figure 10A–C). However, 
the antineuropathic effects of S1RA disappeared in longer periods 
after treatment was discontinued: allodynia and hyperalgesia 
values on days 11 and 14 were indistinguishable from those in the 
vehicle-treated group (Figure 10A–C).
In contrast, acute treatment with S1RA (25 mg/kg, i.p.) had 
no significant effect on mechanical or heat hypersensitivities 
(Figure 11A and B), but significantly inhibited SNI-induced cold 
hypersensitivity (Figure 11C), in agreement with the previously 
commented higher sensitivity of S1RA effects on SNI-induced cold 
allodynia with respect to mechanical and heat hypersensitivity. The 
effects of this dose of S1RA lasted longer when administered s.c. 
than i.p. (compare Figure 3C and 11C), suggesting a faster drug 
elimination of the later.
Taking into account that the acute administration of a dose of 
S1RA which lacks of effect on mechanical and heat hypersensitivity 
FIGURE 5 | Time course of the effects of a single s.c. injection of S1RA (64–128 mg/kg) or saline on mechanical allodynia (A) and heat hyperalgesia (B) in 
female WT and σ1-KO mice with SNI 7 days after surgery. The von Frey threshold (A) and latency to hind paw withdrawal in the Hargreaves test (B) were evaluated 
1 day before (baseline, BL) and 7 days (day 7) after surgery in the paw ipsilateral to the surgery. On day 7 the responses to test stimuli were recorded immediately 
before (time 0) and at several times (30, 90, and 180 min) after injection of the drug or saline. Each point and vertical line represent the mean ± SEM of the values 
obtained in 8–14 animals. Statistically significant differences between S1RA- and saline-treated groups at the same time after treatment were found in WT mice 
(**P < 0.01) but not in σ1-KO mice (two-way repeated-measures ANOVA followed by Bonferroni test).
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and induced only a transient effect on cold allodynia, but the 
repeated treatment with this same dose of S1RA induced a 
marked and long-lasting effect on the three outcomes examined, 
we conclude that repeated treatment with this drug results in an 
improvement of its effects.
Concentration of S1RA in Plasma and Brain 
Tissue After Repeated Administration
To test whether the sustained antinociceptive effects induced 
by the repeated administration of S1RA 12 h after the 
discontinuation of drug treatment (i.e., on day 10) was due 
FIGURE 6 | The opioid antagonists naloxone hydrochloride (Nx) and naloxone methiodide (NxM) reversed the effects of S1RA on mechanical allodynia and heat 
hyperalgesia but not on cold allodynia in female and male WT mice with SNI 7 days after surgery. In female mice, mechanical allodynia (A), heat hyperalgesia (B), 
and cold allodynia (C) were evaluated 1 day before (baseline, BL) and 7 days (day 7) after surgery. Identical procedures were performed on male mice for the 
determination of mechanical (D), heat (E), and cold (F) sensitivity. On day 7 the responses to test stimuli in the paw ipsilateral to the surgery were recorded 
immediately before (time 0) and at several times (30, 90, and 180 min) after injections of the drugs (S1RA and opioid antagonists) or saline. Each point and vertical 
line represent the mean ± SEM of the values obtained in 8–14 animals. Statistically significant differences in comparison to the saline+S1RA group: **P < 0.01 
(two-way repeated-measures ANOVA followed by Bonferroni test).
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to the presence of any drug remaining in the organism, the 
concentrations of S1RA in plasma and brain tissue were 
measured 30 min and 12 h after the last dose of S1RA. On day 
9 of repeated treatment, 30 min after the last administration 
of S1RA (25 mg/kg, i.p.), we found significant levels of this 
σ1 antagonist in both plasma and brain, with a much higher 
concentration in the latter (red bars in Figure 12A and B). In 
contrast, 12 h after the last administration, we observed no 
appreciable levels of this σ1 antagonist in any sample analyzed 
(Figure 12A and B).
DISCUSSION
The main findings of the present study are that: 1) pharmacological 
antagonism or genetic inactivation of σ1 receptors reduces 
neuropathic pain induced by peripheral nerve transection (SNI 
model); 2) the ameliorative effects on SNI-induced hypersensitivity 
to mechanical and heat stimuli (but not to cold stimuli) produced 
by σ1 receptor antagonism are mediated by modulation of the 
endogenous opioid system; and 3) repeated treatment with S1RA 
induces prolonged ameliorative effects which lasted longer than 
the presence of the drug in the organism.
FIGURE 7 | The opioid antagonists Nx and NxM had no effect per se in female WT mice with SNI 7 days after surgery. Mechanical allodynia (A), heat hyperalgesia (B), 
and cold allodynia (C) were evaluated 1 day before (baseline, BL) and 7 days (day 7) after surgery in the paw ipsilateral to the surgery. On day 7 the responses to 
test stimuli were recorded immediately before (time 0) and at several times (30, 90, and 180 min) after injection of the opioid antagonist or saline. Each point and 
vertical line represent the mean ± SEM of the values obtained in 8–10 animals. Neither of the treatments produced statistically significant differences in comparison 
to the saline group (two-way repeated-measures ANOVA followed by Bonferroni test).
FIGURE 8 | Time course of the effects of a single s.c. injection of morphine (0.5–2 mg/kg) or saline on mechanical allodynia (A), heat hyperalgesia (B), 
and cold allodynia (C) in female WT mice with SNI 7 days after surgery. The von Frey threshold (A), latency to hind paw withdrawal in the Hargreaves test 
(B), and duration of hind paw licking or biting in the acetone test (C) were recorded 1 day before (baseline, BL) and 7 days (day 7) after surgery in the 
paw ipsilateral to the surgery. On day 7 the responses to test stimuli were recorded immediately before (time 0) and at several times (30, 90, and 180 min) 
after injection of the drug or saline. Each point and vertical line represent the mean ± SEM of the values obtained in 8–13 animals. Statistically significant 
differences between morphine- and saline-treated groups at the same time after treatment: *P < 0.05; **P < 0.01 (two-way repeated-measures ANOVA 
followed by Bonferroni test).
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Basal sensitivity to mechanical, cold, and heat stimulation in 
mice lacking σ1 receptors, in the absence of nerve injury, did not 
differ from that in WT mice. This is in agreement with previous 
studies (de la Puente et al., 2009; Nieto et al., 2012) and suggests that 
the basic mechanisms of nociceptive transduction are intact in mice 
lacking σ1 receptors. We showed that WT mice after SNI surgery 
developed mechanical, cold, and heat hypersensitivities with time 
courses similar to those previously reported in mice (Bourquin 
et al., 2006; Guida et al., 2015; Liu et al., 2015; Cobos et al., 2018). 
In addition, the extent of the sensory hypersensitivity was similar 
between female and male WT mice. In mice lacking σ1 receptors 
from either sex, however, SNI surgery induced a very different 
pattern of painful hypersensitivity: these mutant mice did not 
develop cold allodynia and showed significantly less mechanical 
allodynia, whereas they developed heat hyperalgesia normally. This 
is consistent with previous work in other neuropathic pain models, 
which found that σ1-KO mice had significantly reduced mechanical 
and cold allodynia induced by chemotherapy (Nieto et al., 2012) or 
FIGURE 9 | Differential ability of Nx and NxM to reverse the effects of morphine on mechanical allodynia, heat hyperalgesia, and cold allodynia in female WT mice 
with SNI 7 days after surgery. Mechanical allodynia (A), heat hyperalgesia (B), and cold allodynia (C) were evaluated 1 day before (baseline, BL) and 7 days (day 7) 
after surgery in the paw ipsilateral to the surgery. On day 7 the responses to test stimuli were recorded immediately before (time 0) and at several times (30, 90, and 
180 min) after injections of the drugs (morphine and opioid antagonists) or saline. Each point and vertical line represent the mean ± SEM of the values obtained in 
8–14 animals. Statistically significant differences in comparison to the saline+morphine group: *P < 0.05; **P < 0.01 (two-way repeated-measures ANOVA followed 
by Bonferroni test).
FIGURE 10 | Time course of the effect of repeated treatment with S1RA on mechanical allodynia (A), heat hyperalgesia (B), and cold allodynia (C) induced by SNI 
in female WT mice. The mice were treated twice daily with either saline or S1RA (25 mg/kg, i.p.). The first injection was administrated 30 min before SNI surgery. 
Responses were recorded in each animal before SNI (baseline, BL) and 30 min after the administration of S1RA or saline on day 7 in the paw ipsilateral to the 
surgery. Treatment was continued until day 9 and the mice were evaluated again on days 10, 11, and 14 postsurgery. The black horizontal line at the top of each 
figure illustrates the duration of treatment with S1RA or saline. Each point and vertical line represent the mean ± SEM of the values obtained in 10–14 animals. 
Statistically significant differences between S1RA- and saline-treated groups on the same day after treatment: *P < 0.05; **P < 0.01 (two-way repeated-measures 
ANOVA followed by Bonferroni test).
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by partial sciatic nerve ligation (de la Puente et al., 2009); the latter 
study also found that heat hyperalgesia developed normally (de la 
Puente et al., 2009). However, it was recently reported that σ1-KO 
mice showed, in addition to the reduction in mechanical allodynia, 
a significant attenuation of heat hypersensitivity induced by spinal 
cord injury (Castany et al., 2018) or diabetic neuropathy (Wang 
et al., 2018). Taken together, studies with σ1-KO mice suggest that 
the role of σ1 receptors during neuropathic pain depends on the 
sensory modality explored and the type of injury.
The acute pharmacological antagonism of σ1 receptor with 
S1RA administration, once the painful neuropathy was fully 
established in WT mice, significantly (although partially) 
attenuated mechanical allodynia and fully reversed cold 
hypersensitivity induced by SNI. In addition, and in contrast 
to our findings with σ1-KO mice, acute S1RA administration 
also abolished SNI-induced heat hyperalgesia in female or 
male WT mice. Previous studies in other neuropathic pain 
models reported that the systemic acute administration of σ1 
antagonists (including S1RA) reversed not only neuropathic 
cold and mechanical allodynia (Nieto et al., 2012; Romero et al., 
2012; Gris et al., 2016; Espinosa-Juárez et al., 2017b; Paniagua 
et al., 2017; Castany et al., 2018; Wang et al., 2018) but also heat 
FIGURE 11 | Time course of the effects of a single i.p. injection of S1RA (25 mg/kg) or saline on mechanical allodynia (A), heat hyperalgesia (B), and cold allodynia (C) 
in female WT mice with SNI 7 days after surgery. Responses were recorded in each animal before SNI (baseline, BL) and 7 days (day 7) after surgery. On day 7 the 
responses to test stimuli in the paw ipsilateral to the surgery were recorded immediately before (time 0) and at two times (30 and 90 min) after injection of the drug 
or saline. Each point and vertical line represent the mean ± SEM of the values obtained in six to eight animals. Statistically significant differences between S1RA- 
and saline-treated groups at the same time after treatment: **P < 0.01 (two-way repeated-measures ANOVA followed by Bonferroni test).
FIGURE 12 | Concentrations of S1RA in plasma and brain tissue after its repeated administration in female WT. The levels of S1RA were measured by high-
performance liquid chromatography–triple quadrupole mass spectrometry (HPLC-MS/MS) in plasma (A) and brain homogenates (B). Mice were treated from day 
0 to day 9 twice daily with either saline or S1RA (25 mg/kg, i.p.). Plasma and brain samples were obtained on day 9 (30 min after S1RA or saline administration) 
and day 10 (12 h after S1RA or saline administration). Each bar and vertical line represent the mean ± SEM of the values obtained in five to six animals (A and 
B). Statistically significant differences between the levels 30 min after S1RA administration and the rest of the experimental groups: **P < 0.01 (two-way ANOVA 
followed by Bonferroni test).
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hyperalgesia (Díaz et al., 2012; Romero et al., 2012; Paniagua et 
al., 2017; Castany et al., 2018; Wang et al., 2018), findings which 
are also in clear agreement with our results. Therefore, there is an 
apparent divergence between the reduction in heat hyperalgesia 
in S1RA-treated WT mice, and the normal development of heat 
hypersensitivity in σ1-KO mice after SNI. This inconsistency 
cannot be explained by a nonspecific off-target effect of S1RA, 
because here we show that the acute ameliorative effects induced 
by S1RA in all three sensory modalities explored in the present 
study were abolished by the selective σ1 agonist PRE-084, which 
did not show any effects “per se,” as previously described in a 
different neuropathic pain model (Espinosa-Juárez et al., 2017b). 
In addition, the administration of S1RA to σ1-KO mice had no 
effect on SNI-induced mechanical and heat hypersensitivity. 
Therefore, these results argue in favor of a σ1-mediated action 
induced by this drug. In fact, it is known that S1RA has exquisite 
selectivity for σ1 receptors (Romero et al., 2012). The discrepancy 
between the effect of genetic and pharmacological inhibition 
of σ1 receptors on heat hypersensitivity was also found in other 
studies of neuropathic pain (de la Puente et al., 2009; Romero 
et al., 2012) and during inflammatory pain (Tejada et  al., 
2014). In addition, conflicting results between σ1 knockout 
and pharmacological antagonism have been reported in the 
modulation of opioid-induced analgesia in nociceptive heat pain 
(Vidal-Torres et al., 2013). Studies of pain mechanisms that used 
the genetic and pharmacological inhibition of other receptors 
have also obtained contradictory results (Petrus et al., 2007; 
Bonin et al., 2011), which have been attributed to compensatory 
mechanisms developed by mutant mice. Therefore, this issue 
appears to be a general concern in experiments with knockout 
animals. Taking into account these antecedents, we suggest that 
σ1-KO mice develop these purported compensatory mechanisms 
in heat pain pathways but not in other pain pathways in which 
the knockout replicated the effects of σ1 antagonists.
After peripheral nerve injury, neuroinflammatory processes 
occur with the recruitment of myriad immune cells at the site 
of injury (Treutlein et al., 2018) and in the dorsal root ganglia 
(Kwon et al., 2013), where the somas of peripheral sensory 
neurons are located. These immune cells release a variety of 
inflammatory mediators that contribute to neuropathic pain, 
but they also produce EOPs which have analgesic potential 
(reviewed in Refs. Ji et al., 2014; Stein, 2016; Tejada et al., 2018). 
In our experimental conditions, opioid antagonism caused by the 
administration of naloxone or its peripherally restricted analog 
naloxone methiodide did not exacerbate pain hypersensitivity 
in any sensory modality explored, suggesting that the tonic 
endogenous activity of the opioid system is limited in SNI mice. 
Importantly, the ameliorative effects induced by S1RA in SNI-
induced mechanical and heat hypersensitivity were reversed by 
both naloxone and naloxone methiodide. These results suggest 
that σ1 inhibition ameliorates SNI-induced mechanical and heat 
hypersensitivity through a mechanism dependent on peripherally 
produced EOPs, whose actions are tonically limited by σ1 
receptors. This dependence on the peripheral opioid system of the 
effects induced by S1RA on mechanical and heat hypersensitivity 
was seen in both female and male mice, indicating a lack of sexual 
dimorphism in these effects. It was recently reported that σ1 
antagonism produced opioid-dependent antihyperalgesic effects 
during inflammation by enhancing the action of EOPs released 
by immune cells that accumulate at the inflamed site (Tejada et al., 
2017). Interestingly, σ1 receptors are expressed in the somas of all 
peripheral sensory neurons (Mavlyutov et al., 2016; Montilla-
García et al., 2018), at a much higher density than in central pain-
related areas (Sánchez-Fernández et al., 2014). In light of these 
antecedents, it can be hypothesized that our results for the effects 
of S1RA on neuropathic mechanical and heat hypersensitivity may 
also be attributable to the enhancement, by σ1 antagonism, of the 
peripheral antinociceptive actions of EOPs produced by immune 
cells. Further research is guaranteed to determine the exact EOP/
EOPs involved in the opioid-dependent effects induced by σ1 
antagonism during neuropathic pain.
It has been reported that peripheral immune cells do not 
contribute equally to every modality of sensory hypersensitivity 
after peripheral nerve injury. In fact, peripheral macrophages and 
T-cells promote both mechanical allodynia and heat hyperalgesia 
(Kobayashi et al., 2015; Cobos et al., 2018), whereas their influence 
in cold allodynia is very limited, which suggest that it is due to 
neuronal mechanisms rather than to neuroimmune interactions 
(Cobos et al., 2018). Here we show that the effects of S1RA on cold 
allodynia in either female or male mice are independent of opioid 
activation, which is consistent with the known inhibitory effects 
of S1RA on neuronal sensitization (Romero et al., 2012; Paniagua 
et al., 2017). In this connection it was previously reported that the 
effects of σ1 antagonists in other pain models such as capsaicin-
induced secondary hypersensitivity (Entrena et al., 2009) or 
formalin-induced pain (Tejada et al., 2017) were not sensitive 
to naloxone treatment. Taking into account the wide variety of 
protein partners (other than opioid receptors) that benefit from 
the chaperoning actions of σ1 receptors (reviewed in Refs. Su 
et al., 2016; Sánchez-Fernández et al., 2017), it is not surprising 
that multiple opioid and nonopioid mechanisms simultaneously 
participate on the ameliorative effects of σ1 antagonism.
We also found that whereas morphine only partially reversed 
mechanical allodynia, it was able to fully suppress heat and cold 
hypersensitivity induced by SNI—effects which resemble those 
induced by S1RA. The effects of morphine on mechanical and 
heat hypersensitivity, but not on cold allodynia, were sensitive 
to the peripheral opioid antagonist naloxone methiodide. These 
results suggest that peripheral opioid effects are markedly weaker 
in cold allodynia than in mechanical or heat hypersensitivity, and 
are consistent with the absence of peripherally mediated opioid 
effects on the inhibition of cold allodynia induced by S1RA.
We also tested the effects of the repeated administration of 
S1RA, which was administered preemptively before surgery 
and subsequently administered twice a day during the next 9 
days. Plasma levels of S1RA in mice after repeated treatment 
with this drug were similar to or lower than the levels of this 
drug in humans after daily oral S1RA treatment at therapeutic 
doses (Abadias et al., 2013; Bruna et al., 2018). We found that 
the sustained administration of S1RA induced prolonged 
ameliorative effects on the hypersensitivity to mechanical, 
heat, and cold stimuli, without any evidence of tolerance to the 
antineuropathic effects during the evaluation period. This may 
be relevant given that some effects of S1RA, as shown in the 
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present study, involve the opioid system, and it is well known that 
sustained opioid treatment induced analgesic tolerance (Morgan 
and Christie, 2011). Therefore, although we show that the effects 
of σ1 antagonism are partially mediated by the opioid system, 
this does not necessarily imply the development of analgesic 
tolerance.
We evaluated the effects of the repeated administration of 
S1RA starting before neuropathic pain was established, and 
found that it had marked effects on mechanical, heat, and 
cold hypersensitivity. However, when the same dose of S1RA 
was acutely administered once neuropathic pain was fully 
established, its effects were limited and observed only in cold 
allodynia. Therefore, S1RA showed higher efficacy after repeated 
treatment than after a single treatment. It is unlikely that the 
greater effects induced by repeated treatment of S1RA were due 
to drug accumulation, since we previously showed that repeated 
treatment with the same protocol as in the present study did 
not result in increased levels of S1RA with time (Romero et al., 
2012). In addition, here we show that 12 h after treatment was 
discontinued, there were no appreciable levels of S1RA in either 
plasma or brain tissue, indicating the complete elimination of 
this compound between doses. Interestingly, although no S1RA 
remained in the organism 12 h after its last administration, 
drug effects were still significantly evident in all three sensory 
modalities. Our results are consistent with previous studies in 
which the repeated administration of σ1 antagonists (including 
S1RA) consistently induced a long-lasting reduction of the 
development of mechanical, cold, and heat hypersensitivity 
in models of neuropathic pain of different etiologies (Nieto et 
al., 2012; Gris et al., 2016; Paniagua et al., 2017). It is unclear 
whether these prolonged effects induced by the repeated 
treatment with S1RA might be due to the production of an 
active metabolite not detected in our determinations. However, 
it is known that σ1 receptors can influence gene transcription, 
which might account for the long-lasting effects observed (Tsai 
et al., 2015). In fact, repeated treatment with the σ1 agonist PRE-
084, which is chemically unrelated to S1RA, had long-lasting 
proallodynic effects (Entrena et al., 2016). Taken together, 
these results suggest that the repeated treatment with σ1 ligands 
might have sustained pharmacodynamic effects, not restricted 
to S1RA and its possible active metabolites, although further 
experiments are needed to clarify this issue. Regardless of the 
precise mechanism, our data suggest that repeated treatment 
with S1RA may have potential therapeutic utility in the context 
of neuropathies induced by nerve transection during surgery, 
when the precise time of nerve injury can be anticipated and 
preventive treatment can be given.
In summary, this study demonstrates that σ1 antagonism may be 
a potentially effective therapeutic tool to inhibit neuropathic pain 
induced by peripheral nerve transection. In addition, our findings 
support the notion that σ1 antagonism induces both opioid-
dependent and -independent effects during neuropathic pain.
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